A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)

Summary

It is a phase Ⅱ,open-label, single-line, Multiple cohorts, Multicenter study assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins mutation patients with Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC).

Timeline

Start

2023-07-21

Primary completion

2025-03-06

Completion

2026-12-30

Publications

• Yang JJ, Mu Y, Wang ZH, Duan JC, Zhang Y, Wu L, Zhong H, Zhao J, Yao Y, Wang P, Li XL, Yang RX, Min XH, Lv DQ, Xu HP, Fu ZM, Shen B, Sun LH, Wang CL, Zhou JY, Xu RL, Ma HW, Zhao YQ, Shi HP, Zhang PL, Xue WZ, Han D, Zheng Y, Wu YL. Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study. J Thorac Oncol. 2026 Mar;21(3):103518. doi: 10.1016/j.jtho.2025.11.008. Epub 2025 Nov 15.

Drugs

Indications